Abstract:
Photodynamic therapy (PDT) is a relatively new, minimal invasive alternate treatment methodology for malignant and non-malignant diseases. The principle of PDT lies in activation of photosensitizer by suitable wavelength in the presence of cellular molecular oxygen. Formation of reactive oxygen species (ROS) ultimately leads to the tissue death via oxidation of cellular organelles. In this study, set of experiments were design to study the efficacy of photosense (AlPS-4) mediated PDT in combination with chemotherapeutic agents (Doxorubicin and dacarbazine). The proposed study was carried out on rhabdomyosarcoma (RD), a human cancer cell line In-vitro. RD culture was treated with photosense (25 nM, 250 nM) as a control treatment and demonstrated that the selected PS dose has no toxic effects. Thereafter chemo-drugs alone with different non-toxic concentration regime (25 nM, 100 nM and 500 nM) were administered to RD cell culture at 3hours, 24 hours & 48 hours. Therapeutic response on RD culture was measured with calorimetric assay, MMT (3-(4,5Dimethylthiazol-2-Yl)-2,5-DiphenyltetrazoliumBromide). Individual chemo drugs toxicity was observed within ± %10 even at higherconcentration 500 nM is around 9% for both chemo drugs. RD culture showed higher killing ( 50%) compared to chemo drugs alone when exposed to PS in the presence of suitable laser light (?= 630 nm). Furthermore PDT was combine with chemo-drugs (doxorubicin and dacarbazine) with different concentrations (50 nM, 100 nM&500 nM,) and time (3 hours, 24 hours &48 hours) in different repeated order. It was observed that dox-PDT initiated higher cell killing both at 24 hours and 48 hours as compared to the rest of treatment arms. While in PDTdacarbazine cell death was observed 54% at 24 hours. Furthermore in the presence of both doxorubicin and dacarbazine low efficacy was measured with PDT. So this study suggests that PDT can have good therapeutic outcome with doxorubicin.
Page(s):
314-314
DOI:
DOI not available
Published:
Journal: Abstract Book on International Conference on Food and Applied Sciences (ICFAS-23) 3-5 August 23, Volume: 0, Issue: 0, Year: 2023
Keywords:
Doxorubicin
,
Dacarbazine
,
Photodynamic therapy
,
Rhabdomyosarcoma